Nicofetamide

Nicofetamide

SCHEMBL254029

O=C(NC(Cc1ccccc1)c1ccccc1)c1cccnc1

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 1/20 0.67
LMNA P02545 1/20 0.60
CTRC Q99895 1/20 0.59
CYP2C9 P11712 3/20 0.58
CYP2C19 P33261 3/20 0.58
CYP3A4 P08684 2/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2D6 P10635 1/20 0.58
EPHX2 P34913 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MEN1 O00255 1/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
KMT2A Q03164 1/20 0.56
ALDH1A1 P00352 1/20 0.52
HTT P42858 1/20 0.52
NCOA1 Q15788 1/20 0.52
NCOA3 Q9Y6Q9 1/20 0.52
GPR132 Q9UNW8 4/20 0.52
DHPS P49366 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nicofetamide SCHEMBL29500848 1.00 ECE1 (0.67) ECE1LMNACTRCCYP2C9CYP2C19
SCHEMBL30037998 0.85 GPR132 (0.69) ECE1LMNACTRCCYP2C9CYP2C19
SCHEMBL3497405 0.85 GPR132 (0.69) ECE1LMNACTRCCYP2C9CYP2C19
SCHEMBL2229201 0.85 GPR132 (0.69) ECE1LMNACTRCCYP2C9CYP2C19
SCHEMBL10435308 0.84 CYP2C9 (0.58) ECE1LMNACTRCCYP2C9CYP2C19
SCHEMBL1817969 0.83 ECE1 (0.70) ECE1LMNACTRCCYP2C9CYP2C19
SCHEMBL23489730 0.83 ECE1 (0.65) ECE1LMNACTRCCYP2C9CYP2C19
SCHEMBL3078645 0.82 LMNA (0.76) ECE1LMNACTRCCYP2C9CYP2C19
SCHEMBL7415738 0.82 ECE1 (0.64) ECE1LMNACTRCCYP2C9CYP2C19
SCHEMBL27520437 0.82 ECE1 (0.64) ECE1LMNACTRCCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021054927-A2 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2021-03-25 WO claimed
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2020-02-13 US claimed
US-9622969-B2 Polymer conjugated protein micelles SOUTH DAKOTA STATE UNIV (US) 2017-04-18 US claimed
US-20140370110-A1 POLYMER CONJUGATED PROTEIN MICELLES SOUTH DAKOTA STATE UNIVERSITY (US) 2014-12-18 US claimed
US-20030195212-A1 Novel melanocortin receptor agonists and antagonists MELACURE THERAPEUTICS AB (SE) 2003-10-16 US claimed
EP-1254114-A2 MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS Melacure Therapeutics AB (SE) 2002-11-06 EP claimed
WO-2001055106-A2 NOVEL MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS MELACURE THERAPEUTICS AB (SE) 2001-08-02 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-2214716-B1 HYDROXYAPATITE-TARGETING MULTIARM POLYMERS AND CONJUGATES MADE THEREFROM NEKTAR THERAPEUTICS (US) 2021-11-17 EP disclosed
EP-3902567-A2 TREATMENT OF RESPIRATORY DISORDERS WITH ARACHIDONATE15-LIPOXYGENASE (ALOX15) INHIBITORS Regeneron Pharmaceuticals, Inc. (US) 2021-11-03 EP disclosed
CN-113423435-A Treatment of respiratory disorders using arachidonic acid 15-lipoxygenase (ALOX15) inhibitors 雷杰纳荣制药公司 2021-09-21 CN disclosed
WO-2021054927-A2 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2021-03-25 WO disclosed
US-20200254070-A1 Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors REGENERON PHARMACEUTICALS, INC. 2020-08-13 US disclosed
WO-1999053920-A1 USE OF VITAMIN PP COMPOUNDS KLINGE PHARMA GMBH (DE) 1999-10-28 WO disclosed
WO-1999015210-A2 BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS NOVEN PHARMACEUTICALS, INC. (US) 1999-04-01 WO disclosed
US-5719197-A DRUG DELIVERY NOVEN PHARMACEUTICALS, INC. (US) 1998-02-17 US disclosed
US-5656286-A BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE NOVEN PHARMACEUTICALS, INC. (US) 1997-08-12 US disclosed
WO-1996040084-A1 COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT NOVEN PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
US-5446070-A Flexible, finite, bioadhesive, therapeutical agent in solid form NOVER PHARMACEUTICALS, INC. (US) 1995-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195212-A1 Novel melanocortin receptor agonists and antagonists MC1R, MC5R, MC4R ECE1 1589/4885LMNA 4570/4885CTRC 3202/4885
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS GSTK1, GSTO1, GSTM2 ECE1 2237/4885LMNA 3751/4885CTRC 3455/4885
US-20140370110-A1 POLYMER CONJUGATED PROTEIN MICELLES MTDH, PSMG3, GHITM ECE1 3013/4885LMNA 1032/4885CTRC 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.